These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 16197359)
1. Rasagiline in the pharmacotherapy of Parkinson's disease--a review. Rascol O Expert Opin Pharmacother; 2005 Oct; 6(12):2061-75. PubMed ID: 16197359 [TBL] [Abstract][Full Text] [Related]
2. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Stocchi F; Rabey JM Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884 [TBL] [Abstract][Full Text] [Related]
3. Rasagiline: a review of its use in the management of Parkinson's disease. Oldfield V; Keating GM; Perry CM Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172 [TBL] [Abstract][Full Text] [Related]
4. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. Hoy SM; Keating GM Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669 [TBL] [Abstract][Full Text] [Related]
5. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages]. Pagonabarraga J; Rodríguez-Oroz MC Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. Müller T Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
8. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
9. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235 [TBL] [Abstract][Full Text] [Related]
10. Rasagiline: a guide to its use in Parkinson's disease. Keating GM; Lyseng-Williamson KA; Hoy SM CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482 [TBL] [Abstract][Full Text] [Related]
12. Rasagiline for the treatment of Parkinson's disease: an update. Stocchi F; Fossati C; Torti M Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897 [TBL] [Abstract][Full Text] [Related]
13. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G; Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect Nagai M; Hattori N Nihon Yakurigaku Zasshi; 2020; 155(3):187-194. PubMed ID: 32378642 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Tolosa E; Stern MB Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487 [TBL] [Abstract][Full Text] [Related]
16. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease. Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744 [TBL] [Abstract][Full Text] [Related]
19. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
20. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related] [Next] [New Search]